Peter ten Dijke

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/5857775/publications.pdf

Version: 2025-02-01

437 PR articles	52,510 PR citations	598 118 PR h-index	1220 224 g-index
483 documents	60809 doc citations	599 128 h-index	69851 citing authors

#	Article	IF	Citations
1	ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-Î²1 activation. Gut, 2025, 74, 424-439.	16.8	31
2	The TGF-Î² mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding. EMBO Reports, 2025, 26, 218-244.	5.2	7
3	TGM6 is a helminth secretory product that mimics TGF-Î² binding to TGFBR2 to antagonize signaling in fibroblasts. Nature Communications, 2025, 16, .	13.7	6
4	Extracellular Vesicles Secreted by Cancerâ€Associated Fibroblasts Drive Nonâ€Invasive Cancer Cell Progression to Metastasis via TGFâ€Î² Signalling Hyperactivation. Journal of Extracellular Vesicles, 2025, 14, .	12.6	6
5	Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity. Nature Communications, 2025, 16, .	13.7	7
6	ECM1 expression in chronic liver disease: Regulation by EGF/STAT1 and IFNÎ³/NRF2 signalling. JHEP Reports, 2025, 7, 101423.	4.5	0
7	Novel high throughput 3D ECM remodeling assay identifies MEK as key driver of fibrotic fibroblast activity. Materials Today Bio, 2025, 32, 101800.	7.0	0
8	Cytokines from parasites: manipulating host responses by molecular mimicry. Biochemical Journal, 2025, 482, 433-449.	3.8	5
9	Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1â€“WAVE2 interaction. Proceedings of the National Academy of Sciences of the United States of America, 2025, 122, .	7.5	0
10	Opposing roles for ADAMTS2 and ADAMTS14 in myofibroblast differentiation and function. Journal of Pathology, 2024, 262, 90-104.	4.9	7
11	Interstitial flow potentiates TGF-Î²/Smad-signaling activity in lung cancer spheroids in a 3D-microfluidic chip. Lab on A Chip, 2024, 24, 422-433.	5.1	12
12	Smad7 palmitoylation by the S-acyltransferase zDHHC17 enhances its inhibitory effect on TGF-Î²/Smad signaling. Journal of Biological Chemistry, 2024, 300, 107462.	2.2	9
13	EMT-related cell-matrix interactions are linked to states of cell unjamming in cancer spheroid invasion. IScience, 2024, 27, 111424.	3.6	4
14	ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver. Hepatology, 2023, 77, 1211-1227.	10.1	30
15	ST3GAL5 â€catalyzed gangliosides inhibit TGF â€Î²â€induced epithelialâ€mesenchymal transition via TÎ²RI degradation. EMBO Journal, 2023, 42, .	7.3	34
16	Opposing USP19 splice variants in TGF-Î² signaling and TGF-Î²-induced epithelialâ€“mesenchymal transition of breast cancer cells. Cellular and Molecular Life Sciences, 2023, 80, .	5.5	14
17	Intertumoral Differences Dictate the Outcome of TGF-Î² Blockade on the Efficacy of Viro-Immunotherapy. Cancer Research Communications, 2023, 3, 325-337.	2.8	8
18	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cellular and Molecular Immunology, 2023, 20, 318-340.	12.7	50

#	Article	IF	Citations
19	Differential optineurin expression controls TGFÎ² signaling and is a key determinant for metastasis of triple negative breast cancer. International Journal of Cancer, 2023, 152, 2594-2606.	4.3	8
20	Imaging the TGFÎ² type I receptor in pulmonary arterial hypertension. EJNMMI Research, 2023, 13, .	2.7	1
21	LncRNA LITATS1 suppresses TGFâ€Î²â€induced EMT and cancer cell plasticity by potentiating TÎ²RI degradation. EMBO Journal, 2023, 42, .	7.3	61
22	The lncRNA LETS1 promotes TGF-Î²â€“induced EMT and cancer cell migration by transcriptionally activating a TÎ²R1-stabilizing mechanism. Science Signaling, 2023, 16, .	5.4	22
23	TGF-Î² Type I Receptor Signaling in Melanoma Liver Metastases Increases Metastatic Outgrowth. International Journal of Molecular Sciences, 2023, 24, 8676.	4.4	3
24	Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells. Science Advances, 2023, 9, .	10.9	19
25	CD44 acts as a coreceptor for cell-specific enhancement of signaling and regulatory T cell induction by TGM1, a parasite TGF-Î² mimic. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.5	22
26	Simultaneously targeting extracellular vesicle trafficking and TGF-Î² receptor kinase activity blocks signaling hyperactivation and metastasis. Signal Transduction and Targeted Therapy, 2023, 8, .	32.9	14
27	The protein kinase LKB1 promotes selfâ€renewal and blocks invasiveness in glioblastoma. Journal of Cellular Physiology, 2022, 237, 743-762.	4.1	11
28	Follistatinâ€controlled activinâ€HNF4Î±â€coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology, 2022, 75, 322-337.	10.1	25
29	Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy. Pharmaceutics, 2022, 14, 120.	4.9	51
30	RNF12 is regulated by AKT phosphorylation and promotes TGF-Î² driven breast cancer metastasis. Cell Death and Disease, 2022, 13, .	8.5	18
31	Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell, 2022, 185, 379-396.e38.	33.7	799
32	CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. , 2022, 10, e003995.		30
33	Transforming growth factor-Î² challenge alters the N-, O-, andÂglycosphingolipid glycomes in PaTu-S pancreatic adenocarcinoma cells. Journal of Biological Chemistry, 2022, 298, 101717.	2.2	8
34	TGFÎ² selects for proâ€stemness over proâ€invasive phenotypes during cancer cell epithelialâ€“mesenchymal transition. Molecular Oncology, 2022, 16, 2330-2354.	4.1	13
35	A Programmable Multifunctional 3D Cancer Cell Invasion Micro Platform. Small, 2022, 18, .	11.5	9
36	Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10. Nature Communications, 2022, 13, .	13.7	16

#	Article	IF	Citations
37	Microfluidics meets 3D cancer cell migration. Trends in Cancer, 2022, 8, 683-697.	10.4	61
38	OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF-Î²2 type I receptor. Signal Transduction and Targeted Therapy, 2022, 7, .	32.9	36
39	Dynamic Visualization of TGF-Î²2/SMAD3 Transcriptional Responses in Single Living Cells. Cancers, 2022, 14, 2508.	3.8	16
40	Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. Cancers, 2022, 14, 2724.	3.8	18
41	Synthesis and preclinical evaluation of [11C]LR111 and [18F]EW-7197 as PET tracers of the activin-receptor like kinase-5. Nuclear Medicine and Biology, 2022, 112-113, 9-19.	0.3	1
42	Low Transforming Growth Factor-Î²2 Pathway Activity in Cervical Adenocarcinomas. Frontiers in Oncology, 2022, 12, .	2.6	5
43	TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling. Molecular Cancer Research, 2022, 20, 1516-1531.	3.1	20
44	USP8 promotes cancer progression and extracellular vesicleâ€mediated CD8 + T cell exhaustion by deubiquitinating the TGF â€Î²2 receptor	7.3	77
45	Breast cancer cell-derived extracellular vesicles promote CD8+â€‰T cell exhaustion via TGF-Î²2 type II receptor signaling. Nature Communications, 2022, 13, .	13.7	127
46	Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment. Molecular Biomedicine, 2022, 3, .	8.2	39
47	E3 Ubiquitin Ligases: Key Regulators of TGFÎ²2 Signaling in Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 476.	4.4	25
48	A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis. Genome Biology, 2021, 22, .	8.1	22
49	Targeting TGFÎ²2 signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, .	32.9	346
50	TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing. Journal of Visualized Experiments, 2021, , .	0.3	9
51	TGF-Î²2-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors. Frontiers in Cell and Developmental Biology, 2021, 9, .	3.6	42
52	Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva. Biomedicines, 2021, 9, 213.	3.4	13
53	Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell, 2021, 28, 653-670.e11.	16.4	51
54	Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors. Cancers, 2021, 13, 2951.	3.8	6

#	Article	IF	Citations
55	Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-Î² signalling. Angiogenesis, 2021, 25, 99-112.	7.3	16
56	Cripto favors chondrocyte hypertrophy via TGFâ€Î² SMAD1/5 signaling during development of osteoarthritis. Journal of Pathology, 2021, 255, 330-342.	4.9	17
57	Metabolic Reprogramming of Mammary Epithelial Cells during TGF-Î²-Induced Epithelial-to-Mesenchymal Transition. Metabolites, 2021, 11, 626.	3.4	15
58	Therapeutic targeting of TGF-Î² in cancer: hacking a master switch of immune suppression. Clinical Science, 2021, 135, 35-52.	6.2	66
59	The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma. Cell Death and Disease, 2021, 12, .	8.5	6
60	Breast cancer dormancy is associated with a 4NG1 state and not senescence. Npj Breast Cancer, 2021, 7, .	6.4	20
61	Cancer associated-fibroblast-derived exosomes in cancer progression. Molecular Cancer, 2021, 20, .	29.2	285
62	VprBP mitigates TGF-Î² and Activin signaling by promoting Smurf1-mediated type I receptor degradation. Journal of Molecular Cell Biology, 2020, 12, 138-151.	3.5	15
63	THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 523, 307-314.	2.1	14
64	Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFÎ²-Induced Breast Cancer Metastasis. Clinical Cancer Research, 2020, 26, 1460-1473.	6.8	124
65	Current perspectives on inhibitory SMAD7 in health and disease. Critical Reviews in Biochemistry and Molecular Biology, 2020, 55, 691-715.	6.7	68
66	TGFâ€Î² signaling in liver metastasis. Clinical and Translational Medicine, 2020, 10, .	5.5	48
67	Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Letters, 2020, 493, 41-54.	8.6	24
68	Mechanotransduction is a context-dependent activator of TGF-Î² signaling in mesenchymal stem cells. Biomaterials, 2020, 259, 120331.	12.1	41
69	Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos. Journal of the American Chemical Society, 2020, 142, 16825-16841.	15.0	71
70	Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish. DMM Disease Models and Mechanisms, 2020, 13, .	2.0	9
71	TGF-Î²-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering. Frontiers in Cell and Developmental Biology, 2020, 8, .	3.6	211
72	Secreted BMP antagonists and their role in cancer and bone metastases. Bone, 2020, 137, 115455.	3.5	28

#	Article	IF	Citations
73	MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2020, 21, 4130.	4.4	5
74	Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors. Bone, 2020, 138, 115472.	3.5	107
75	Differential O- and Glycosphingolipid Glycosylation in Human Pancreatic Adenocarcinoma Cells With Opposite Morphology and Metastatic Behavior. Frontiers in Oncology, 2020, 10, .	2.6	24
76	A Signaling Crosstalk between BMP9 and HGF/c-Met Regulates Mouse Adult Liver Progenitor Cell Survival. Cells, 2020, 9, 752.	4.7	13
77	Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. Trends in Immunology, 2020, 41, 406-420.	10.5	63
78	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. Cancer Cell, 2020, 37, 308-323.e12.	33.0	79
79	On-Target Anti-TGF-Î² Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?. Frontiers in Cell and Developmental Biology, 2020, 8, .	3.6	183
80	TGFÎ² and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness. Oncogene, 2020, 39, 4436-4449.	6.5	83
81	Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stressâ€“Activated FOXO1 to Trigger Î²-Cell Failure. Diabetes, 2020, 69, 193-204.	4.2	30
82	Development of a 96-well plate sample preparation method for integrated N - and O -glycomics using porous graphitized carbon liquid chromatography-mass spectrometry. Molecular Omics, 2020, 16, 355-363.	2.4	64
83	Role of glycosylation in TGF-Î² signaling and epithelial-to-mesenchymal transition in cancer. Protein and Cell, 2020, 12, 89-106.	3.7	66
84	Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29684-29690.	7.5	34
85	Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells. Journal of Visualized Experiments, 2020, , .	0.3	15
86	Uncovering the deubiquitinase activity landscape of breast cancer. Oncoscience, 2020, 7, 85-87.	1.2	2
87	Autophagy contributes to BMP type 2 receptor degradation andÂdevelopment of pulmonary arterial hypertension. Journal of Pathology, 2019, 249, 356-367.	4.9	45
88	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. European Respiratory Journal, 2019, 54, 1802400.	8.7	33
89	In vivo imaging of TGFÎ² signalling components using positron emission tomography. Drug Discovery Today, 2019, 24, 2258-2272.	6.6	8
90	GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Communication and Signaling, 2019, 17, .	7.9	44

#	Article	IF	Citations
91	Generation of Fibrodysplasia ossificans progressiva and control integration free iPSC lines from periodontal ligament fibroblasts. Stem Cell Research, 2019, 41, 101639.	0.6	8
92	Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressivaâ€Derived Endothelial Cells. JBMR Plus, 2019, 3, .	2.1	37
93	Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Research, 2019, 21, .	4.8	144
94	c-Met activation leads to the establishment of a TGFÎ²-receptor regulatory network in bladder cancer progression. Nature Communications, 2019, 10, .	13.7	57
95	Role of soluble endoglin in BMP9 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17800-17808.	7.5	75
96	Generation of non-standard macrocyclic peptides specifically binding TSC-22 homologous gene-1. Biochemical and Biophysical Research Communications, 2019, 516, 445-450.	2.1	5
97	Epigenetic Reprogramming of TGF-Î² Signaling in Breast Cancer. Cancers, 2019, 11, 726.	3.8	65
98	TGF-Î²-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences, 2019, 20, 2767.	4.4	984
99	DIPG-13. A NOVEL MOUSE MODEL REVEALS UNEXPECTED MECHANISMS OF ACTION OF ACVR1 MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, ii71-ii71.	1.0	0
100	Combined Inhibition of TGF-Î² Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells, 2019, 8, 320.	4.7	104
101	JNK-Dependent cJun Phosphorylation Mitigates TGFÎ²- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses. Cells, 2019, 8, 1481.	4.7	18
102	A Perspective on the Development of TGF-Î² Inhibitors for Cancer Treatment. Biomolecules, 2019, 9, 743.	4.2	164
103	Inflammation induces endothelialâ€toâ€mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. Journal of Pathology, 2019, 247, 333-346.	4.9	177
104	TGF-Î² Family Signaling Pathways in Cellular Dormancy. Trends in Cancer, 2019, 5, 66-78.	10.4	77
105	Bone morphogenetic protein receptor signal transduction in human disease. Journal of Pathology, 2019, 247, 9-20.	4.9	206
106	TGFÎ²-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cellular and Molecular Life Sciences, 2019, 77, 2103-2123.	5.5	220
107	JUNB governs a feed-forward network of TGFÎ² signaling that aggravates breast cancer invasion. Nucleic Acids Research, 2018, 46, 1180-1195.	15.5	102
108	TGF-β family co-receptor function and signaling. Acta Biochimica Et Biophysica Sinica, 2018, 50, 12-36.	2.0	194

#	Article	IF	Citations
109	TGF-Î² Signaling in Control of Cardiovascular Function. Cold Spring Harbor Perspectives in Biology, 2018, 10, a022210.	7.2	336
110	Bone Morphogenetic Proteins in Vascular Homeostasis and Disease. Cold Spring Harbor Perspectives in Biology, 2018, 10, a031989.	7.2	140
111	P177Inflammation-induced EndMT facilitates BMP-9-mediated vascular calcification in a BMP type II receptor (BMPR2) dependent manner. Cardiovascular Research, 2018, 114, S47-S47.	5.5	0
112	Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. Clinical Cancer Research, 2018, 24, 6331-6344.	6.8	158
113	Epithelialâ€“mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. Oncogene, 2018, 37, 6195-6211.	6.5	150
114	Bone morphogenetic protein 9 as a key regulator of liver progenitor cells in DDCâ€induced cholestatic liver injury. Liver International, 2018, 38, 1664-1675.	3.9	32
115	The therapeutic potential of targeting the endothelial-to-mesenchymal transition. Angiogenesis, 2018, 22, 3-13.	7.3	97
116	Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. Oncogenesis, 2017, 6, e294-e294.	5.6	22
117	TMED10 Protein Interferes with Transforming Growth Factor (TGF)-Î² Signaling by Disrupting TGF-Î² Receptor Complex Formation. Journal of Biological Chemistry, 2017, 292, 4099-4112.	2.2	30
118	Targeting TGF-Î² Signaling in Cancer. Trends in Cancer, 2017, 3, 56-71.	10.4	898
119	Fluid shear stress-induced TGF-Î²/ALK5 signaling in renal epithelial cells is modulated by MEK1/2. Cellular and Molecular Life Sciences, 2017, 74, 2283-2298.	5.5	35
120	FAF1 phosphorylation by AKT accumulates TGF-Î² type II receptor and drives breast cancer metastasis. Nature Communications, 2017, 8, .	13.7	43
121	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cellular and Molecular Life Sciences, 2017, 74, 2979-2995.	5.5	100
122	SUMO-triggered ubiquitination of NR4A1 controls macrophage cell death. Cell Death and Differentiation, 2017, 24, 1530-1539.	13.3	52
123	BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut, 2017, 66, 939-954.	16.8	141
124	Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish. Journal of Visualized Experiments, 2017, , .	0.3	31
125	Endoglin as an Important Regulator of Colorectal Cancer Invasion and Metastasis. Gastroenterology, 2017, 152, S87.	0.9	0
126	Disparate phospho-Smad2 levels in advanced type 2 diabetes patients with diabetic nephropathy and early experimental db/db mouse model. Renal Failure, 2017, 39, 629-642.	2.5	10

#	Article	IF	Citations
127	Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nature Communications, 2017, 8, .	13.7	113
128	TGFÎ²1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity. Arthritis Research and Therapy, 2017, 19, .	4.0	61
129	New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB Journal, 2017, 31, 238-255.	0.6	30
130	Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation. Frontiers in Physiology, 2017, 8, .	2.8	38
131	TGF-Î²-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. International Journal of Molecular Sciences, 2017, 18, 2157.	4.4	326
132	ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models. Frontiers in Cell and Developmental Biology, 2017, 5, .	3.6	4
133	Smad6 determines BMP-regulated invasive behaviour of breast cancer cells in a zebrafish xenograft model. Scientific Reports, 2016, 6, .	3.4	45
134	Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3589-3599.	0.4	45
135	c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/Î²-Catenin/Axin2 Pathway. Cancer Research, 2016, 76, 3364-3375.	3.8	121
136	Regulation of the TGF-Î² pathway by deubiquitinases in cancer. International Journal of Biochemistry and Cell Biology, 2016, 76, 135-145.	2.6	30
137	Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression. American Journal of Pathology, 2016, 186, 1874-1889.	3.4	30
138	Immunoregulation by members of the TGFÎ² superfamily. Nature Reviews Immunology, 2016, 16, 723-740.	53.8	329
139	Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochemical Society Transactions, 2016, 44, 1142-1149.	4.1	43
140	A current perspective on applications of macrocyclicâ€peptideâ€based highâ€affinity ligands. Biopolymers, 2016, 106, 889-900.	2.9	24
141	Expression of TGFÎ²-family signalling components in ageing cartilage: age-related loss of TGFÎ² and BMP receptors. Osteoarthritis and Cartilage, 2016, 24, 1235-1245.	5.5	42
142	TGFâ€Î² signalling and liver disease. FEBS Journal, 2016, 283, 2219-2232.	5.4	568
143	The rationale for targeting TGFâ€Î² in chronic liver diseases. European Journal of Clinical Investigation, 2016, 46, 349-361.	3.1	73
144	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. Clinical Cancer Research, 2016, 22, 96-106.	6.8	50

#	Article	IF	Citations
145	Fibulin-4 deficiency increases TGF-Î² signalling in aortic smooth muscle cells due to elevated TGF-Î²2 levels. Scientific Reports, 2015, 5, .	3.4	28
146	Disorganised stroma determined on preâ€treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular Oncology, 2015, 9, 1120-1128.	4.1	35
147	A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. Journal of Virology, 2015, 89, 8318-8333.	3.6	73
148	Signal Transduction: Gain of Activin Turns Muscle into Bone. Current Biology, 2015, 25, R1136-R1138.	3.6	3
149	The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFÎ²1. Osteoarthritis and Cartilage, 2015, 23, 985-995.	5.5	31
150	Bone morphogenetic protein signaling in bone homeostasis. Bone, 2015, 80, 43-59.	3.5	203
151	SLUG Is Expressed in Endothelial Cells Lacking Primary Cilia to Promote Cellular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 616-627.	6.0	47
152	Transforming Growth Factor Î² Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology, 2015, 148, 1427-1437.e8.	0.9	59
153	Genetic depletion and pharmacological targeting of Î±v integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Research, 2015, 17, .	4.8	53
154	Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva. European Journal of Human Genetics, 2015, 23, 1431-1431.	3.0	24
155	Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure. DMM Disease Models and Mechanisms, 2015, , .	2.0	8
156	Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovascular Research, 2015, 108, 278-287.	5.5	89
157	Inhibition of TGFÎ² type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice. Archives of Toxicology, 2015, 90, 347-357.	5.8	35
158	Targeting BMP signalling in cardiovascular disease and anaemia. Nature Reviews Cardiology, 2015, 13, 106-120.	35.7	228
159	Ter94/VCP Is a Novel Component Involved in BMP Signaling. PLoS ONE, 2014, 9, e114475.	2.3	11
160	Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-Î² signalling. Nature Communications, 2014, 5, .	13.7	179
161	Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFÎ² Type 1 Receptor Modulation by Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2014, 3, e142.	5.5	25
162	Wild-type p53 inhibits pro-invasive properties of TGF-Î²3 in breast cancer, in part through regulation of EPHB2, a new TGF-Î² target gene. Breast Cancer Research and Treatment, 2014, 148, 7-18.	2.4	24

#	Article	IF	Citations
163	Targeting TGF-Î² Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-Î² Type I Receptor. Molecular Therapy - Nucleic Acids, 2014, 3, e156.	5.5	33
164	Time-resolved dissection of early phosphoproteome and ensuing proteome changes in response to TGF-Î². Science Signaling, 2014, 7, .	5.4	42
165	Functionality of Endothelial Cells and Pericytes From Human Pluripotent Stem Cells Demonstrated in Cultured Vascular Plexus and Zebrafish Xenografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 177-186.	6.0	192
166	Loss of SMAD4 Alters BMP Signaling to Promote Colorectal Cancer Cell Metastasis via Activation of Rho and ROCK. Gastroenterology, 2014, 147, 196-208.e13.	0.9	163
167	P348Impaired macrophage polarization in endoglin haplo-insufficiency leading to defective tissue repair is recovered by counter balance the TGFbeta pathway. Cardiovascular Research, 2014, 103, S63.4-S63.	5.5	0
168	The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. British Journal of Cancer, 2014, 112, 122-130.	5.5	74
169	ENDOGLIN Is Dispensable for Vasculogenesis, but Required for Vascular Endothelial Growth Factor-Induced Angiogenesis. PLoS ONE, 2014, 9, e86273.	2.3	65
170	TRAF4 Promotes TGF-Î² Receptor Signaling and Drives Breast Cancer Metastasis. Molecular Cell, 2013, 51, 559-572.	13.3	220
171	Animal models of chronic liver diseases. American Journal of Physiology - Renal Physiology, 2013, 304, G449-G468.	3.3	200
172	Signaling interplay between transforming growth factor-Î² receptor and PI3K/AKT pathways in cancer. Trends in Biochemical Sciences, 2013, 38, 612-620.	6.7	243
173	Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nature Medicine, 2013, 19, 421-428.	33.0	86
174	Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab on A Chip, 2013, 13, 3562.	5.1	147
175	Snail and Slug, key regulators of TGF-Î²-induced EMT, are sufficient for the induction of single-cell invasion. Biochemical and Biophysical Research Communications, 2013, 435, 58-63.	2.1	128
176	UBE2O negatively regulates TRAF6-mediated NF-Î°B activation by inhibiting TRAF6 polyubiquitination. Cell Research, 2013, 23, 366-377.	12.4	83
177	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Experimental Medicine, 2013, 210, 563-579.	9.2	120
178	Transforming Growth Factor-Î² (TGF-Î²)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation. Journal of Biological Chemistry, 2013, 288, 30708-30719.	2.2	175
179	The prognostic role of TGF-Î² signaling pathway in breast cancer patients. Annals of Oncology, 2013, 24, 384-390.	10.0	87
180	Endoglin for tumor imaging and targeted cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 421-435.	3.7	40

#	Article	IF	Citations
181	Fineâ€tuning BMP7 signalling in adipogenesis by UBE2O/E2â€230Kâ€mediated monoubiquitination of SMAD6. EMBO Journal, 2013, 32, 996-1007.	7.3	84
182	Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy. Expert Opinion on Investigational Drugs, 2013, 22, 1371-1383.	3.9	36
183	Transforming growth factor-Î² signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Research, 2013, 15, .	4.8	112
184	Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva. PLoS ONE, 2013, 8, e69096.	2.3	36
185	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	10.6	405
186	Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling. PLoS ONE, 2013, 8, e62295.	2.3	57
187	Mutational Analysis of Sclerostin Shows Importance of the Flexible Loop and the Cystine-Knot for Wnt-Signaling Inhibition. PLoS ONE, 2013, 8, e81710.	2.3	30
188	Ubiquitin-specific Protease 4 Mitigates Toll-like/Interleukin-1 Receptor Signaling and Regulates Innate Immune Activation. Journal of Biological Chemistry, 2012, 287, 11002-11010.	2.2	80
189	Vanilloid Receptor-1 Regulates Neurogenic Inflammation in Colon and Protects Mice from Colon Cancer. Cancer Research, 2012, 72, 1705-1716.	3.8	59
190	Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting. Journal of Biological Chemistry, 2012, 287, 18551-18561.	2.2	93
191	Fas-associated Factor 1 Is a Scaffold Protein That Promotes Î²-Transducin Repeat-containing Protein (Î²-TrCP)-mediated Î²-Catenin Ubiquitination and Degradation. Journal of Biological Chemistry, 2012, 287, 30701-30710.	2.2	34
192	Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva. Current Pharmaceutical Design, 2012, 18, 4087-4092.	2.4	5
193	TGFÎ² Signaling in Liver Regeneration. Current Pharmaceutical Design, 2012, 18, 4103-4113.	2.4	64
194	Tgf-Î² Signaling In Duchenne Muscular Dystrophy. Future Neurology, 2012, 7, 209-224.	0.5	5
195	19 HOW ARE HEPATOCYTES PRIMED FOR TGF-Î² MEDIATED APOPTOSIS? BONE MORPHOGENETIC PROTEIN (BMP)-9 AS DEADLY CO-FACTOR IN VITRO AND IN VIVO. Journal of Hepatology, 2012, 56, S9.	4.2	0
196	A Covalently Dimerized Recombinant Human Bone Morphogenetic Protein-15 Variant Identifies Bone Morphogenetic Protein Receptor Type 1B as a Key Cell Surface Receptor on Ovarian Granulosa Cells. Endocrinology, 2012, 153, 1509-1518.	2.5	43
197	655 Studying TGF- Signaling Using a High Resolution, Quantitative Mass Spectrometric Approach. European Journal of Cancer, 2012, 48, S155.	4.9	0
198	Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Research, 2012, 14, .	4.8	36

#	Article	IF	Citations
199	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	33.7	414
200	USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-Î² type I receptor. Nature Cell Biology, 2012, 14, 717-726.	16.3	292
201	138. The prognostic role of TGF-Î² signaling pathway in breast cancer patients. European Journal of Surgical Oncology, 2012, 38, 777.	0.9	0
202	Cellâ€type specific regulation of myostatin signaling. FASEB Journal, 2012, 26, 1462-1472.	0.6	63
203	RNF12 Controls Embryonic Stem Cell Fate and Morphogenesis in Zebrafish Embryos by Targeting Smad7 for Degradation. Molecular Cell, 2012, 46, 650-661.	13.3	93
204	Wnt/Î²-catenin signaling changes C2C12 myoblast proliferation and differentiation by inducing Id3 expression. Biochemical and Biophysical Research Communications, 2012, 419, 83-88.	2.1	18
205	LRP8 mediates Wnt/Î²-catenin signaling and controls osteoblast differentiation. Journal of Bone and Mineral Research, 2012, 27, 2065-2074.	4.9	57
206	Shear induced collateral artery growth modulated by endoglin but not by ALK1. Journal of Cellular and Molecular Medicine, 2012, 16, 2440-2450.	4.0	38
207	The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. European Journal of Cancer, 2012, 48, 3429-3438.	4.9	43
208	Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia. Pregnancy Hypertension, 2012, 2, 358-367.	1.5	23
209	USP4 is regulated by Akt phosphorylation and deubiquitylates TGF-beta type I receptor. Nature Precedings, 2012, , .	0.0	0
210	TGFÎ² Signaling and Cardiovascular Diseases. International Journal of Biological Sciences, 2012, , 195-213.	8.5	89
211	TGF-Î² signalling and its role in cancer progression and metastasis. Cancer and Metastasis Reviews, 2012, 31, 553-568.	6.9	412
212	BMP signaling in vascular diseases. FEBS Letters, 2012, 586, 1993-2002.	2.7	254
213	Nonsynonymous variants in theSMAD6gene predispose to congenital cardiovascular malformation. Human Mutation, 2012, 33, 720-727.	4.5	128
214	Regulation of endothelial barrier function by TGFâ€Î² type I receptor ALK5: Potential role of contractile mechanisms and heat shock protein 90. Journal of Cellular Physiology, 2012, 227, 759-771.	4.1	21
215	Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy. Cellular and Molecular Life Sciences, 2012, 70, 407-423.	5.5	39
216	Specific interactions between Smad proteins and AP-1 components determine TGFÎ²-induced breast cancer cell invasion. Oncogene, 2012, 32, 3606-3615.	6.5	99

#	Article	IF	Citations
217	Interaction with colon cancer cells hyperactivates TGF-Î² signaling in cancer-associated fibroblasts. Oncogene, 2012, 33, 97-107.	6.5	244
218	TGFÎ² Signaling and Cardiovascular Diseases. International Journal of Biological Sciences, 2012, 8, 195-213.	8.5	161
219	Exploring anti-TGF-Î² therapies in cancer and fibrosis. Growth Factors, 2011, 29, 140-152.	1.7	144
220	Temporal Smad7 Transgene Induction in Mouse Epidermis Accelerates Skin Wound Healing. American Journal of Pathology, 2011, 179, 1768-1779.	3.4	37
221	O.13 Interference of myostatin and TGF-beta signaling by antisense-mediated exon skipping in ALK4/5 receptors. Neuromuscular Disorders, 2011, 21, 704.	0.7	0
222	Spheroid Assay to Measure TGF-Î²-induced Invasion. Journal of Visualized Experiments, 2011, , .	0.3	28
223	ALK2 mutation in a patient with Down's syndrome and a congenital heart defect. European Journal of Human Genetics, 2011, 19, 389-393.	3.0	40
224	BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiology of Disease, 2011, 41, 353-360.	5.1	35
225	Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-Î². Experimental Cell Research, 2011, 317, 131-142.	3.1	12
226	TGF-Î² Signaling in Breast Cancer Cell Invasion and Bone Metastasis. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 97-108.	3.1	152
227	Elevated transforming growth factor Î² and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis and Tissue Repair, 2011, 4, .	2.8	60
228	Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Medical Genomics, 2011, 4, .	1.7	42
229	The dynamic roles of TGFâ€Î² in cancer. Journal of Pathology, 2011, 223, 206-219.	4.9	353
230	Endoglin promotes TGF-Î²/Smad1 signaling in scleroderma fibroblasts. Journal of Cellular Physiology, 2011, 226, 3340-3348.	4.1	72
231	TgfÎ²/Alk5 signaling is required for shear stress induced klf2 expression in embryonic endothelial cells. Developmental Dynamics, 2011, 240, 1670-1680.	1.7	63
232	Biphasic effects of transforming growth factor Î² on bone morphogenetic proteinâ€“induced osteoblast differentiation. Journal of Bone and Mineral Research, 2011, 26, 1178-1187.	4.9	84
233	Fas-associated factor 1 antagonizes Wnt signaling by promoting Î²-catenin degradation. Molecular Biology of the Cell, 2011, 22, 1617-1624.	2.5	52
234	TGFÎ² Activates Mitogen- and Stress-activated Protein Kinase-1 (MSK1) to Attenuate Cell Death. Journal of Biological Chemistry, 2011, 286, 5003-5011.	2.2	28

#	Article	IF	Citations
235	GSK3Î² inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Molecular Biology of the Cell, 2011, 22, 3533-3540.	2.5	54
236	TGF-Î²1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovascular Research, 2011, 91, 510-518.	5.5	39
237	Lack of Primary Cilia Primes Shear-Induced Endothelial-to-Mesenchymal Transition. Circulation Research, 2011, 108, 1093-1101.	13.2	188
238	BMP-7 inhibits TGF-Î²-induced invasion of breast cancer cells through inhibition of integrin Î²3 expression. Cellular Oncology (Dordrecht), 2011, 35, 19-28.	4.1	57
239	Age-dependent alteration of TGF-Î² signalling in osteoarthritis. Cell and Tissue Research, 2011, 347, 257-265.	2.7	135
240	Regulation of endothelial cell plasticity by TGF-Î². Cell and Tissue Research, 2011, 347, 177-186.	2.7	323
241	TGF-Î² in progression of liver disease. Cell and Tissue Research, 2011, 347, 245-256.	2.7	692
242	ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. Journal of Bone and Mineral Research, 2010, 25, 1208-1215.	4.9	155
243	Signaling by members of the TGF-Î² family in vascular morphogenesis and disease. Trends in Cell Biology, 2010, 20, 556-567.	12.1	378
244	Elevated TGFÎ²â€“Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. Journal of Pathology, 2010, 222, 21-31.	4.9	93
245	Annexin A1 regulates TGF-Î² signaling and promotes metastasis formation of basal-like breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6340-6345.	7.5	203
246	Identification of a Key Residue Mediating Bone Morphogenetic Protein (BMP)-6 Resistance to Noggin Inhibition Allows for Engineered BMPs with Superior Agonist Activity. Journal of Biological Chemistry, 2010, 285, 12169-12180.	2.2	113
247	Matrix Metalloproteinase-14 (MT1-MMP)â€“Mediated Endoglin Shedding Inhibits Tumor Angiogenesis. Cancer Research, 2010, 70, 4141-4150.	3.8	247
248	In Situ Proximity Ligation Detection of c-Jun/AP-1 Dimers Reveals Increased Levels of c-Jun/Fra1 Complexes in Aggressive Breast Cancer Cell Lines in Vitro and in Vivo. Molecular and Cellular Proteomics, 2010, 9, 1982-1990.	3.0	25
249	Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. Journal of Experimental Medicine, 2010, 207, 85-100.	9.2	164
250	Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways. Journal of Biological Chemistry, 2010, 285, 41614-41626.	2.2	164
251	TMEPAI, a Transmembrane TGF-Î²-Inducible Protein, Sequesters Smad Proteins from Active Participation in TGF-Î² Signaling. Molecular Cell, 2010, 37, 123-134.	13.3	152
252	5-Aminosalicylic acid inhibits TGF-Î²1 signalling in colorectal cancer cells. Cancer Letters, 2010, 287, 82-90.	8.6	22

#	Article	IF	Citations
253	Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene, 2010, 30, 334-345.	6.5	79
254	The TGF-Î²/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Research and Treatment, 2010, 128, 657-666.	2.4	197
255	VEGF and inhibitors of TGFÎ² type-I receptor kinase synergistically promote blood-vessel formation by inducing Î±5-integrin expression. Journal of Cell Science, 2009, 122, 3294-3302.	2.4	92
256	Smad3 Is a Key Nonredundant Mediator of Transforming Growth Factor Î² Signaling in Nme Mouse Mammary Epithelial Cells. Molecular Cancer Research, 2009, 7, 1342-1353.	3.1	28
257	Dominant-Negative ALK2 Allele Associates With Congenital Heart Defects. Circulation, 2009, 119, 3062-3069.	18.1	100
258	Ski coâ€repressor complexes maintain the basal repressed state of the TGFâ€Î² target gene, SMAD7, via HDAC3 and PRMT5. Genes To Cells, 2009, 14, 17-28.	1.4	61
259	Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activation. Laboratory Investigation, 2009, 89, 800-810.	3.2	20
260	Ionizing Radiation Shifts the PAI-1/ID-1 Balance and Activates Notch Signaling in Endothelial Cells. International Journal of Radiation Oncology Biology Physics, 2009, 73, 506-513.	1.5	84
261	T.P.1.04 Dual exon skipping in myostatin and dystrophin as a potential therapy for Duchenne muscular dystrophy. Neuromuscular Disorders, 2009, 19, 577.	0.7	0
262	Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. Radiotherapy and Oncology, 2009, 92, 484-491.	2.0	41
263	Transforming growth factor-beta signaling and tumor angiogenesis. Frontiers in Bioscience - Landmark, 2009, 14, 4848.	5.7	109
264	279 BONE MORPHOGENETIC PROTEIN (BMP)-9: A NEW MEMBER OF THE TGF-Î² SUPERFAMILY WHICH IS SECRETED BY ACTIVATED HEPATIC STELLATE CELLS. Journal of Hepatology, 2009, 50, S110.	4.2	2
265	Autocrine Bone Morphogenetic Protein-9 Signals through Activin Receptor-like Kinase-2/Smad1/Smad4 to Promote Ovarian Cancer Cell Proliferation. Cancer Research, 2009, 69, 9254-9262.	3.8	115
266	Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene, 2009, 29, 1351-1361.	6.5	176
267	Shear stress modulates TGFâ€beta signaling and EMT in endothelial cells. FASEB Journal, 2009, 23, .	0.6	0
268	Endoglin in angiogenesis and vascular diseases. Angiogenesis, 2008, 11, 79-89.	7.3	310
269	Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis and Rheumatism, 2008, 58, 2528-2537.	6.1	77
270	ALK1 Opposes ALK5/Smad3 Signaling and Expression of Extracellular Matrix Components in Human Chondrocytes. Journal of Bone and Mineral Research, 2008, 23, 896-906.	4.9	147

#	Article	IF	Citations
271	VE-cadherin is a critical endothelial regulator of TGF-Î² signalling. EMBO Journal, 2008, 27, 993-1004.	7.3	155
272	Transforming Growth Factor Î² and Wound Healing in Human Cholesteatoma. Laryngoscope, 2008, 118, 94-98.	1.4	28
273	Transforming Growth Factor Î²â€“Induced Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis?. Trends in Cardiovascular Medicine, 2008, 18, 293-298.	7.1	159
274	The Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers. Gastroenterology, 2008, 134, 1332-1341.e3.	0.9	155
275	Two novel type II receptors mediate BMP signalling and are required to establish leftâ€“right asymmetry in zebrafish. Developmental Biology, 2008, 315, 55-71.	1.9	55
276	Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling. Journal of Bone and Joint Surgery - Series A, 2008, 90, 31-35.	3.3	199
277	L- and S-endoglin differentially modulate TGFÎ²1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. Journal of Cell Science, 2008, 121, 913-919.	2.4	112
278	Oral administration of GW788388, an inhibitor of TGF-Î² type I and II receptor kinases, decreases renal fibrosis. Kidney International, 2008, 73, 705-715.	5.3	203
279	TGF-Î² signaling in vascular biology and dysfunction. Cell Research, 2008, 19, 116-127.	12.4	570
280	Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation. Journal of Bone and Mineral Research, 2007, 22, 19-28.	4.9	252
281	BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of Cell Science, 2007, 120, 964-972.	2.4	509
282	Transforming Growth Factor-Î² Receptor Type I-dependent Fibrogenic Gene Program Is Mediated via Activation of Smad1 and ERK1/2 Pathways. Journal of Biological Chemistry, 2007, 282, 10405-10413.	2.2	177
283	KLF2 Suppresses TGF-Î² Signaling in Endothelium Through Induction of Smad7 and Inhibition of AP-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 532-539.	6.0	113
284	Compensatory signalling induced in the yolk sac vasculature by deletion of TGFÎ² receptors in mice. Journal of Cell Science, 2007, 120, 4269-4277.	2.4	111
285	Signaling by ALK5 mediates TGF-Î²-induced ET-1 expression in endothelial cells: a role for migration and proliferation. Journal of Cell Science, 2007, 120, 1256-1266.	2.4	94
286	BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo. American Journal of Pathology, 2007, 171, 1047-1057.	3.4	194
287	TMEPAI, a transmembrane TGF-Î²-inducible protein, sequesters Smad proteins in TGF-Î² signaling. Nature Precedings, 2007, , .	0.0	0
288	SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Developmental Dynamics, 2007, 236, 606-612.	1.7	43

#	Article	IF	Citations
289	Aberrant Bmp signaling and notochord delamination in the pathogenesis of esophageal atresia. Developmental Dynamics, 2007, 236, 746-754.	1.7	75
290	A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biology, 2007, 8, .	3.6	69
291	Extracellular control of TGFÎ² signalling in vascular development and disease. Nature Reviews Molecular Cell Biology, 2007, 8, 857-869.	78.2	754
292	Negative regulation of TGF-Î² receptor/Smad signal transduction. Current Opinion in Cell Biology, 2007, 19, 176-184.	3.9	369
293	TGF-Î² and BMP7 interactions in tumour progression and bone metastasis. Clinical and Experimental Metastasis, 2007, 24, 609-617.	2.6	112
294	The Tumor Suppressor Smad4 Is Required for Transforming Growth Factor Î²â€“Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells. Cancer Research, 2006, 66, 2202-2209.	3.8	360
295	Methylation of Smad6 by protein arginineN-methyltransferase 1. FEBS Letters, 2006, 580, 6603-6611.	2.7	28
296	A Rate Equation Approach to Elucidate the Kinetics and Robustness of the TGF-Î² Pathway. Biophysical Journal, 2006, 91, 4368-4380.	2.2	51
297	Bone morphogenetic protein signal transduction in bone. Current Medical Research and Opinion, 2006, 22, S7-S11.	2.1	70
298	Smad7-Induced Î²-Catenin Degradation Alters Epidermal Appendage Development. Developmental Cell, 2006, 11, 301-312.	7.7	155
299	Title is missing!. BMC Cell Biology, 2006, 7, 16.	3.6	50
300	An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoter-luciferase construct. Analytical Biochemistry, 2006, 349, 78-86.	2.4	54
301	Id1 is a critical mediator in TGF-Î²-induced transdifferentiation of rat hepatic stellate cells. Hepatology, 2006, 43, 1032-1041.	10.1	137
302	Endoglin Has a Crucial Role in Blood Cellâ€“Mediated Vascular Repair. Circulation, 2006, 114, 2288-2297.	18.1	128
303	New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of Î²-defensins, LL37, and TLR2. European Journal of Immunology, 2005, 35, 1886-1895.	3.2	69
304	TGF-? receptor function in the endothelium. Cardiovascular Research, 2005, 65, 599-608.	5.5	480
305	SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine and Growth Factor Reviews, 2005, 16, 319-327.	10.5	335
306	Transforming Growth Factor-Î²1 to the Bone. Endocrine Reviews, 2005, 26, 743-774.	24.7	668

#	Article	IF	Citations
307	Control of bone formation by osteocytes? lessons from the rare skeletal disorders sclerosteosis and van Buchem disease. BoneKEy Osteovision, 2005, 2, 33-38.	0.4	6
308	Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. Journal of Cell Science, 2004, 117, 4653-4663.	2.4	89
309	Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist. Journal of Experimental Medicine, 2004, 199, 805-814.	9.2	832
310	Defective paracrine signalling by TGFÎ² in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development (Cambridge), 2004, 131, 6237-6247.	3.1	142
311	Nerve growth factor mediates activation of the Smad pathway in PC12 cells. FEBS Journal, 2004, 271, 920-931.	0.2	35
312	Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO Journal, 2004, 23, 541-551.	7.3	227
313	Endoglin promotes endothelial cell proliferation and TGF-Î²/ALK1 signal transduction. EMBO Journal, 2004, 23, 4018-4028.	7.3	630
314	New insights into TGF-Î²â€“Smad signalling. Trends in Biochemical Sciences, 2004, 29, 265-273.	6.7	1,126
315	Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Developmental Dynamics, 2004, 231, 542-550.	1.7	100
316	RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-Î² (TGF-Î²) target gene that negatively regulates transcriptional activity induced by TGF-Î². Biochemical Journal, 2004, 383, 187-199.	3.8	17
317	Gene Array Analysis of Bone Morphogenetic Protein Type I Receptor-Induced Osteoblast Differentiation. Journal of Bone and Mineral Research, 2003, 18, 1177-1185.	4.9	55
318	Controlling mesenchymal stem cell differentiation by TGFÎ² family members. Journal of Orthopaedic Science, 2003, 8, 740-748.	1.2	163
319	Distribution of phosphorylated Smad2 identifies target tissues of TGFÎ² ligands in mouse development. Gene Expression Patterns, 2003, 3, 355-360.	0.9	37
320	Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology, 2003, 125, 178-191.	0.9	360
321	Controlling cell fate by bone morphogenetic protein receptors. Molecular and Cellular Endocrinology, 2003, 211, 105-113.	3.4	183
322	Bone morphogenetic protein signalling in NGF-stimulated PC12 cells. Biochemical and Biophysical Research Communications, 2003, 307, 632-639.	2.1	10
323	Activin Receptor-like Kinase (ALK)1 Is an Antagonistic Mediator of Lateral TGFÎ²/ALK5 Signaling. Molecular Cell, 2003, 12, 817-828.	13.3	660
324	Nuclear Factor YY1 Inhibits Transforming Growth Factor Î²- and Bone Morphogenetic Protein-Induced Cell Differentiation. Molecular and Cellular Biology, 2003, 23, 4494-4510.	2.5	164

#	Article	IF	Citations
325	Elucidation of Smad Requirement in Transforming Growth Factor-Î² Type I Receptor-induced Responses. Journal of Biological Chemistry, 2003, 278, 3751-3761.	2.2	192
326	Transforming Growth Factor-Î²1 (TGF-Î²)â€“induced Apoptosis of Prostate Cancer Cells Involves Smad7-dependent Activation of p38 by TGF-Î²-activated Kinase 1 and Mitogen-activated Protein Kinase Kinase 3. Molecular Biology of the Cell, 2003, 14, 529-544.	2.5	222
327	Transforming Growth Factor-Î²1 Mutations in Camurati-Engelmann Disease Lead to Increased Signaling by Altering either Activation or Secretion of the Mutant Protein. Journal of Biological Chemistry, 2003, 278, 7718-7724.	2.2	108
328	dSmurf Selectively Degrades Decapentaplegic-activated MAD, and Its Overexpression Disrupts Imaginal Disc Development. Journal of Biological Chemistry, 2003, 278, 26307-26310.	2.2	46
329	Smad protein and TGF-Î² signaling in vascular smooth muscle cells. International Journal of Molecular Medicine, 2003, , .	4.4	12
330	Growth Differentiation Factor-9 Induces Smad2 Activation and Inhibin B Production in Cultured Human Granulosa-Luteal Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 755-762.	4.1	115
331	SIGNAL TRANSDUCTION OF BONE MORPHOGENETIC PROTEINS IN OSTEOBLAST DIFFERENTIATION. Journal of Bone and Joint Surgery - Series A, 2003, 85, 34-38.	3.3	92
332	Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Proteinâ€“Induced Activation of Endothelial Cells. Circulation, 2002, 106, 2263-2270.	18.1	286
333	Deficient Smad7 expression: A putative molecular defect in scleroderma. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3908-3913.	7.5	232
334	Identification and Functional Characterization of Distinct Critically Important Bone Morphogenetic Protein-specific Response Elements in the Id1 Promoter. Journal of Biological Chemistry, 2002, 277, 4883-4891.	2.2	811
335	Immunohistochemical Localization of Osteogenetic Protein (OP-1) and Its Receptors in Rabbit Articular Cartilage. Journal of Histochemistry and Cytochemistry, 2002, 50, 1341-1349.	1.5	20
336	Activation of Bone Morphogenetic Protein/Smad Signaling in Bronchial Epithelial Cells during Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 160-169.	3.8	121
337	BMP Pathways Are Involved in Otic Capsule Formation and Epithelialâ€“Mesenchymal Signaling in the Developing Chicken Inner Ear. Developmental Biology, 2002, 251, 380-394.	1.9	83
338	Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells. Molecular and Cellular Endocrinology, 2002, 195, 79-88.	3.4	23
339	Physical and Functional Interaction between GATA-3 and Smad3 Allows TGF-Î² Regulation of GATA Target Genes. Current Biology, 2002, 12, 35-45.	3.6	92
340	Action Range of BMP Is Defined by Its N-Terminal Basic Amino Acid Core. Current Biology, 2002, 12, 205-209.	3.6	166
341	Regulation of cell proliferation by Smad proteins. Journal of Cellular Physiology, 2002, 191, 1-16.	4.1	427
342	The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGFâ€Î²/Smad signalling. Genes To Cells, 2002, 7, 321-331.	1.4	142

#	Article	IF	Citations
343	Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO Journal, 2002, 21, 2580-2590.	7.3	102
344	Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO Journal, 2002, 21, 1743-1753.	7.3	1,023
345	Transforming growth factor Î² signal transduction. Journal of Leukocyte Biology, 2002, 71, 731-740.	2.9	188
346	Diffusion of Nodal Signaling Activity in the Absence of the Feedback Inhibitor Lefty2. Developmental Cell, 2001, 1, 127-138.	7.7	120
347	Transforming growth factor Î² signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. FEBS Letters, 2001, 502, 4-10.	2.7	187
348	Ectopic expression of Smad7 inhibits transforming growth factor-Î² responses in vascular smooth muscle cells. Life Sciences, 2001, 69, 2641-2652.	4.5	13
349	Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. Journal of Cellular Physiology, 2001, 187, 117-123.	4.1	112
350	Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO Journal, 2001, 20, 4132-4142.	7.3	168
351	Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO Journal, 2001, 20, 1663-1673.	7.3	523
352	Transforming growth factor-Î²-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cellular Signalling, 2001, 13, 483-490.	3.5	55
353	Nodal Signaling Uses Activin and Transforming Growth Factor-Î² Receptor-regulated Smads. Journal of Biological Chemistry, 2001, 276, 656-661.	2.2	107
354	The Orphan Receptor Serine/Threonine Kinase ALK7 Signals Arrest of Proliferation and Morphological Differentiation in a Neuronal Cell Line. Journal of Biological Chemistry, 2001, 276, 5140-5146.	2.2	52
355	Interaction between GC Box Binding Factors and Smad Proteins Modulates Cell Lineage-specific Î±2(I) Collagen Gene Transcription. Journal of Biological Chemistry, 2001, 276, 16573-16579.	2.2	75
356	Activation of the TGF- Î² /Activin-Smad2 Pathway during Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 60-68.	3.8	124
357	Apoptosis in podocytes induced by TGF-Î² and Smad7. Journal of Clinical Investigation, 2001, 108, 807-816.	10.6	259
358	Apoptosis in podocytes induced by TGF-Î² and Smad7. Journal of Clinical Investigation, 2001, 108, 807-816.	10.6	556
359	Human mast cell migration in response to members of the transforming growth factor-Î² family. Journal of Leukocyte Biology, 2000, 67, 350-356.	2.9	114
360	Expression of the inhibitory Smad7 in early mouse development and upregulation during embryonic vasculogenesis. Developmental Dynamics, 2000, 218, 663-670.	1.7	20

#	Article	IF	Citations
361	Signaling of transforming growth factorâ€Î² family members through Smad proteins. FEBS Journal, 2000, 267, 6954-6967.	0.2	481
362	Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene, 2000, 19, 4396-4404.	6.5	87
363	Smad7 mediates apoptosis induced by transforming growth factor Î² in prostatic carcinoma cells. Current Biology, 2000, 10, 535-538.	3.6	151
364	Signaling inputs converge on nuclear effectors in TGF-Î² signaling. Trends in Biochemical Sciences, 2000, 25, 64-70.	6.7	343
365	Efficient TGF-Î² Induction of the Smad7 Gene Requires Cooperation between AP-1, Sp1, and Smad Proteins on the Mouse Smad7 Promoter. Journal of Biological Chemistry, 2000, 275, 29023-29030.	2.2	147
366	Role of Smad Proteins and Transcription Factor Sp1 in p21Waf1/Cip1 Regulation by Transforming Growth Factor-Î². Journal of Biological Chemistry, 2000, 275, 29244-29256.	2.2	359
367	Smad and AML Proteins Synergistically Confer Transforming Growth Factor Î²1 Responsiveness to Human Germ-line IgA Genes. Journal of Biological Chemistry, 2000, 275, 3552-3560.	2.2	139
368	The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Research, 2000, 28, 4291-4298.	15.5	103
369	Activin receptor-like kinase 1 modulates transforming growth factor-Î²1 signaling in the regulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2626-2631.	7.5	821
370	Hedgehog Creates a Gradient of DPP Activity in Drosophila Wing Imaginal Discs. Molecular Cell, 2000, 5, 59-71.	13.3	403
371	Correlation between ALK-6 (BMPR-IB) Distribution and Responsiveness to Osteogenic Protein-1 (BMP-7) in Embryonic Mouse Bone Rudiments. Growth Factors, 2000, 17, 177-192.	1.7	21
372	TGF-Î² signaling by Smad proteins. Advances in Immunology, 2000, , 115-157.	6.6	425
373	Endogenous patterns of TGFÎ² superfamily signaling during early Xenopus development. Development (Cambridge), 2000, 127, 2917-2931.	3.1	231
374	Specificity, diversity, and regulation in TGFâ€Î² superfamily signaling. FASEB Journal, 1999, 13, 2105-2124.	0.6	734
375	Expression of TGF-beta related Smad proteins in human epithelial skin tumors.. International Journal of Oncology, 1999, , .	3.8	17
376	Expression of Transforming Growth Factor-Î²1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function1. Endocrinology, 1999, 140, 4300-4310.	2.5	55
377	Differential Inhibition of Smad6 and Smad7 on Bone Morphogenetic Protein- and Activin-mediated Growth Arrest and Apoptosis in B Cells. Journal of Biological Chemistry, 1999, 274, 13637-13642.	2.2	206
378	Localization of Smads, the TGF-Î² Family Intracellular Signaling Components During Endochondral Ossification. Journal of Bone and Mineral Research, 1999, 14, 1145-1152.	4.9	145

#	Article	IF	Citations
379	Chromosomal localization of three human genes encoding bone morphogenetic protein receptors. Mammalian Genome, 1999, 10, 299-302.	2.3	14
380	Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. , 1999, 180, 141-149.		43
381	Molecular analyses of the 15q and 18qSMAD genes in pancreatic cancer. , 1999, 24, 62-71.		54
382	Expression of transforming-growth-factor (TGF)-? receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-?1. , 1999, 80, 756-763.		74
383	Expression of Smad proteins in human colorectal cancer. International Journal of Cancer, 1999, 82, 197-202.	4.3	100
384	Lack of responsiveness to TGF-Î²1 in a thyroid carcinoma cell line with functional type I and type II TGF-Î² receptors and Smad proteins, suggests a novel mechanism for TGF-Î² insensitivity in carcinoma cells. Molecular and Cellular Endocrinology, 1999, 153, 79-90.	3.4	26
385	Xenopus Smad4Î² Is the Co-Smad Component of Developmentally Regulated Transcription Factor Complexes Responsible for Induction of Early Mesodermal Genes. Developmental Biology, 1999, 214, 354-369.	1.9	89
386	Expression of Transforming Growth Factor-Â1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function. Endocrinology, 1999, 140, 4300-4310.	2.5	15
387	TGF-Î² type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. Journal of Cell Science, 1999, 112, 4557-4568.	2.4	389
388	Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 Differentially Regulate Osteogenesis. Journal of Bone and Mineral Research, 1998, 13, 383-392.	4.9	146
389	Direct binding of Smad3 and Smad4 to critical TGFbeta -inducible elements in the promoter of human plasminogen activator inhibitor-type 1gene. EMBO Journal, 1998, 17, 3091-3100.	7.3	1,692
390	Intracellular signaling of osteogenic protein-1 through Smad5 activation. , 1998, 177, 355-363.		74
391	Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat. Journal of Orthopaedic Research, 1998, 16, 314-321.	2.4	32
392	Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes To Cells, 1998, 3, 125-134.	1.4	70
393	Distinct and Overlapping Patterns of Localization of Bone Morphogenetic Protein (BMP) Family Members and a BMP Type II Receptor During Fracture Healing in Rats. Bone, 1998, 22, 605-612.	3.5	266
394	The L45 loop in type I receptors for TGF-Î² family members is a critical determinant in specifying Smad isoform activation. FEBS Letters, 1998, 434, 83-87.	2.7	360
395	Induction of Inhibitory Smad6 and Smad7 mRNA by TGF-Î² Family Members. Biochemical and Biophysical Research Communications, 1998, 249, 505-511.	2.1	336
396	Cloning and Characterization of p70S6KÎ²Defines a Novel Family of p70 S6 Kinases. Biochemical and Biophysical Research Communications, 1998, 253, 470-476.	2.1	51

#	Article	IF	Citations
397	Smad7 Is an Activin-inducible Inhibitor of Activin-induced Growth Arrest and Apoptosis in Mouse B Cells. Journal of Biological Chemistry, 1998, 273, 24293-24296.	2.2	120
398	Identification and Functional Characterization of a Smad Binding Element (SBE) in the JunB Promoter That Acts as a Transforming Growth Factor-Î², Activin, and Bone Morphogenetic Protein-inducible Enhancer. Journal of Biological Chemistry, 1998, 273, 21145-21152.	2.2	530
399	Transforming Growth Factor Î²1 Induces Nuclear Export of Inhibitory Smad7. Journal of Biological Chemistry, 1998, 273, 29195-29201.	2.2	220
400	Physical and Functional Interaction of Murine and Xenopus Smad7 with Bone Morphogenetic Protein Receptors and Transforming Growth Factor-Î² Receptors. Journal of Biological Chemistry, 1998, 273, 25364-25370.	2.2	146
401	Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-Î² Signaling. Journal of Biological Chemistry, 1997, 272, 28107-28115.	2.2	359
402	Transforming Growth Factor (TGF-Î²)-specific Signaling by Chimeric TGF-Î² Type II Receptor with Intracellular Domain of Activin Type IIB Receptor. Journal of Biological Chemistry, 1997, 272, 21187-21194.	2.2	32
403	Identification of Smad2, a Human Mad-related Protein in the Transforming Growth Factor Î² Signaling Pathway. Journal of Biological Chemistry, 1997, 272, 2896-2900.	2.2	155
404	Latent transforming growth factor-Î² complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160. Biochemical Journal, 1997, 324, 427-434.	3.8	28
405	Expression and localization of bone morphogenetic proteins (BMPs) and BMP receptors in ossification of the ligamentum flavum. Bone, 1997, 21, 23-30.	3.5	102
406	DPC4 (SMAD4) mediates transforming growth factor-Î²1 (TGF-Î²1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene, 1997, 14, 1891-1899.	6.5	132
407	TGF-Î² signalling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390, 465-471.	37.9	3,617
408	Identification of Smad7, a TGFÎ²-inducible antagonist of TGF-Î² signalling. Nature, 1997, 389, 631-635.	37.9	1,758
409	TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO Journal, 1997, 16, 5353-5362.	7.3	996
410	Orthotopic ossification of the spinal ligaments of zucker fatty rats: A possible animal model for ossification of the human posterior longitudinal ligament. Journal of Orthopaedic Research, 1997, 15, 820-829.	2.4	23
411	Characterization of a 60-kDa cell surface-associated transforming growth factor-Î² binding protein that can interfere with transforming growth factor-Î² receptor binding. Journal of Cellular Physiology, 1997, 173, 447-459.	4.1	24
412	Bone morphogenetic protein receptors. Bone, 1996, 19, 569-574.	3.5	211
413	Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Molecular and Cellular Endocrinology, 1996, 116, 105-114.	3.4	186
414	Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Current Opinion in Cell Biology, 1996, 8, 139-145.	3.9	254

#	Article	IF	Citations
415	Phosphorylation of Ser165 in TGF-beta type I receptor modulates TGF-beta1-induced cellular responses.. EMBO Journal, 1996, 15, 6231-6240.	7.3	115
416	Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. British Journal of Cancer, 1996, 73, 624-629.	5.5	33
417	A Novel Type I Receptor Serine-Threonine Kinase Predominantly Expressed in the Adult Central Nervous System. Journal of Biological Chemistry, 1996, 271, 30603-30609.	2.2	70
418	Cloning and characterization of a human type II receptor for bone morphogenetic proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7632-7636.	7.5	515
419	A Rat Pituitary Tumor Cell Line (GH3) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 592 Td () Expresses Type I and Type II Receptors a Growth Factor- Î². Journal of Biological Chemistry, 1995, 270, 770-774.	2.2	22
420	Efficient Association of an Amino-terminally Extended Form of Human Latent Transforming Growth Factor-Î² Binding Protein with the Extracellular Matrix. Journal of Biological Chemistry, 1995, 270, 31294-31297.	2.2	81
421	Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.. Journal of Cell Biology, 1995, 130, 217-226.	5.4	469
422	Expression of type I and type IB receptors for activin in midgestation mouse embryos suggests distinct functions in organogenesis. Mechanisms of Development, 1995, 52, 109-123.	2.6	111
423	Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. Journal of Bone and Mineral Research, 1995, 10, 1651-1659.	4.9	158
424	Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology, 1995, 136, 2652-2663.	2.5	81
425	Serine/threonine kinase receptors. Progress in Growth Factor Research, 1994, 5, 55-72.	1.2	72
426	Characterization of in Vivo Phosphorylation of Activin Type II Receptor. Biochemical and Biophysical Research Communications, 1993, 194, 1508-1514.	2.1	19
427	Regulation of the levels of three transforming growth factor Î² mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Molecular and Cellular Endocrinology, 1993, 97, 115-123.	3.4	51
428	Cloning of a TGF$beta; type I receptor that forms a heteromeric complex with the TGF$beta; type II receptor. Cell, 1993, 75, 681-692.	33.7	771
429	Molecular Characterization of Transforming Growth Factor Type ?3. Annals of the New York Academy of Sciences, 1990, 593, 26-42.	4.0	34
430	Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. Journal of Biological Chemistry, 1990, 265, 20533-20538.	2.2	313
431	Growth Factors For Wound Healing. Nature Biotechnology, 1989, 7, 793-798.	29.8	64
432	Identification of another member of the transforming growth factor type beta gene family.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4715-4719.	7.5	295

#	Article	IF	Citations
433	Genomic characterization of the human DNA excision repair geneERCC-1. Nucleic Acids Research, 1987, 15, 9195-9214.	15.5	73
434	<scp>ERBIN</scp> limits epithelial cell plasticity via suppression of <scp>TGF</scp> â€Î² signaling. FEBS Letters, 0, 599, 3103-3112.	2.7	0
435	SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-Î²-induced breast cancer cell plasticity. Nucleic Acids Research, 0, 53, .	15.5	2
436	circTGFBR2(3-6) acts as an assembly platform for RNA-binding protein IGF2BP3 and TGFBR1 mRNA to enhance breast cancer cell plasticity. Cell Death and Differentiation, 0, , .	13.3	0
437	Surfaceâ€Associated Proteins on Extracellular Vesicles Remodel the Tumor Microenvironment by Potentiating TGFâ€Î² Signaling in a Contactâ€Dependent Manner. Advanced Science, 0, 13, .	12.6	0